Peapod Lane Capital LLC bought a new stake in CARGO Therapeutics, Inc. (NASDAQ:CRGX - Free Report) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 219,077 shares of the company's stock, valued at approximately $892,000. Peapod Lane Capital LLC owned about 0.48% of CARGO Therapeutics at the end of the most recent reporting period.
Other hedge funds have also bought and sold shares of the company. Tower Research Capital LLC TRC lifted its position in shares of CARGO Therapeutics by 565.9% during the 4th quarter. Tower Research Capital LLC TRC now owns 5,800 shares of the company's stock valued at $84,000 after acquiring an additional 4,929 shares during the period. Invesco Ltd. purchased a new stake in shares of CARGO Therapeutics in the fourth quarter valued at about $165,000. ProShare Advisors LLC bought a new position in shares of CARGO Therapeutics during the 4th quarter worth approximately $171,000. Intech Investment Management LLC bought a new position in CARGO Therapeutics in the 4th quarter valued at $181,000. Finally, ExodusPoint Capital Management LP purchased a new stake in CARGO Therapeutics during the fourth quarter worth about $183,000. Institutional investors own 93.16% of the company's stock.
Analysts Set New Price Targets
Separately, Jefferies Financial Group boosted their price objective on CARGO Therapeutics from $3.70 to $5.00 and gave the company a "hold" rating in a research note on Tuesday. One analyst has rated the stock with a sell rating and six have assigned a hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $15.40.
Get Our Latest Stock Report on CRGX
CARGO Therapeutics Trading Down 0.2%
Shares of CARGO Therapeutics stock traded down $0.01 during trading on Friday, hitting $4.59. The stock had a trading volume of 1,172,827 shares, compared to its average volume of 704,930. CARGO Therapeutics, Inc. has a 12 month low of $3.00 and a 12 month high of $25.45. The business's 50-day moving average is $4.28 and its 200 day moving average is $5.83. The firm has a market cap of $211.64 million, a price-to-earnings ratio of -0.99 and a beta of 0.28.
CARGO Therapeutics Profile
(
Free Report)
CARGO Therapeutics, Inc, a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies.
Further Reading
Before you consider CARGO Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CARGO Therapeutics wasn't on the list.
While CARGO Therapeutics currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
